Our Sectors
We are experts at what we do
01
Our People
A dedicated team of executive search experts, delivering for you
The Compass Carter Osborne team are healthcare and life science experts. As a trusted advisor we bring decades of search experience and an unparalleled track record of delivery across our dedicated sectors for our investor clients – relied upon time and again to build outstanding leadership teams.
Familiar faces at key industry events, our expertise extends beyond the mere placing of people with our consultants bringing together sector leaders to address key challenges, working in partnership to produce tangible solutions.
02
Expertise
Unearthing rare talent, that drive successful exits
Responsive, adaptable, and emotionally intelligent, Compass Carter Osborne avoid the one-size-fits-all approach to ensure our clients achieve their desired outcome by presenting a broad range of intuitive, tailored solutions, based on specific needs.
03
Our Approach
Tailoring our offering,
to provide a bespoke service
Results driven, not process led, CCO avoid the conformity of a rigid process. Never assumptive, we listen and adopt an agreed approach which most closely delivers to a clients specific needs. Understanding the uniqueness of each role, our people tailor a search to bespoke requirements to ensure solutions that delivers the best possible results first time, every time.
A trusted advisor to the investment community
providing leaders advancing the healthcare and life sciences sectors
What our clients say
“Compass Carter Osborne really delivered for us in our search for a new CEO for Outcomes First Group. It was a vitally important assignment given that we were recruiting a successor for a long standing and highly successful CEO in a sector-leading business. Compass Carter Osborne went above and beyond in developing a deep understanding of the business and our requirements, and in only presenting candidates that closely met these. They think very creatively and their focus was very sharp; they particularly understood the culture of the business. The search was speedy and well organised, with a very high standard of verbal and written feedback. They have a granular knowledge of the sector and because of the way in which they work, we were fully involved throughout and achieved a great result. A really excellent search – thank you.”
Outcomes First Group – Chair
“Compass Carter Osborne started from the very beginning with a detailed, professional explanation of the available position. They spent time to present the great opportunity and chance to accelerate my career but at the same time, the challenge, and the strong expectation from their client.”
Hengrui Therapeutics – VP, Head Biological Drug Discovery
“Compass Carter Osborne delivered on a key appointment for the PFA and the wider football industry. It was a complex brief involving creating an entirely new position. The role was vitally important, with the successful candidate taking on a sensitive and multifaceted responsibility across CTE, concussion and brain health in professional football. CCO led a comprehensive and exhaustive process, developing a deep understanding of the union’s requirements and using his expert knowledge to help scope and evolve the brief throughout the search. The entire process was professional, efficient and well organised, with consistent communication and feedback at every stage.”
The Professional Footballers Association (PFA) – Chief Executive Officer
“I have been so impressed by Luke’s integrity, clear purpose and drive to achieve for his clients. Luke has worked with Priory on a number of things but more recently to source two independent Non Executive Directors and a Director of Talent Acquisition. He has kept us informed, fielded some great candidates and follows up at each stage, even when they have started. I would really recommend him if you are searching for high calibre individuals.”
Priory Group – Chief Executive Officer
“I recently had the pleasure of being appointed to an independent healthcare provider as a NED after being put forward for the role by Luke. Throughout the whole recruitment process I was treated with respect and felt valued. I was particularly impressed with the follow up support after the decision to appoint me, which I have never experienced from other search companies. Luke continued to check in with me to ensure my onboarding went smoothly and that I had settled into the role. Overall, a highly professional and comprehensive approach delivered personally by Luke.”
Priory – Independent Non-Executive Director
“Luke was absolutely brilliant along the journey. He acted as a real partner and was able to answer to all my questions in order to get comfortable with the decision of making the change. His expertise and knowledge of the sector really came out along the process. Most importantly, he was always available when I needed him to be, which is something I valued a lot. In summary, I couldn’t recommend him and Compass Carter Osborne enough.”
AniCura – Group Chief Operating Officer
“We worked with Compass Carter Osborne in the search for our Chief Financial Officer and from the start it was clear they were a good choice of partner. A focus on understanding our needs as a business, and mine personally as a CEO were front of mind for Paul and Kieran. They took the time to listen, understand and not only focus on the functional aspects of the role – but critically, the team fit and culture we are building.
Process, structure and follow-through were like clockwork, and the quality of candidates were of a consistently high-level. I would highly recommend Compass Carter Osborne.”
Renaiss Health – Chief Executive Officer
“I’ve known Tarquin for over 15 years, during which time he has delivered a number of executive assignments at senior level, including COO/executive team and senior management roles in scientific/professional disciplines (his network in the biotech/life-sciences sector is second-to-none!). He works hard to truly understand both the candidate brief and the culture of the company, sets realistic expectations and retains regular contact as an assignment progresses, always providing thorough updates and pragmatic advice. He has the highest levels of professionalism and integrity – he really is a pleasure to work with.”
One Nucleus – Director
“Jamie did a great job – he really took the time to understand our business, our needs and what we were looking for. We knew our brief was specific, yet Jamie met all our expectations with the search. He maintained a high standard of communication and meticulous attention to detail throughout the process. I would recommend Jamie and the Compass Carter Osborne team without hesitation.”
Melrose Education – Chair & CEO
“Our recent work with Compass Carter Osborne was exceptional. The search was perfectly organised, response times were swift, and due to the consultant market knowledge and network, we quickly found our ideal candidate.”
Schoen Clinic – Member of Group Executive
Healthcare news, data and analysis
Via Investors in Healthcare
Switzerland: Teresa Pla Prats joins MTIP as investment associate
Teresa Pla Prats has joined MTIP as an investment associate. She brings experience in deal advisory, commercial due diligence, and strategic consulting across the healthcare ecosystem. Before MTIP, she supported […]
Teresa Pla Prats has joined MTIP as an investment associate. She brings experience in deal advisory, commercial due diligence, and strategic consulting across the healthcare ecosystem. Before MTIP, she supported […]
Switzerland: Teresa Pla Prats joins MTIP as investment associate
November 11, 2025
Healthcare
Life Sciences
News
People
Switzerland
UK: Warwick Capital Partners announces sale of Danforth Care Homes
Warwick Capital Partners, the UK-based global private equity and credit firm, has announced the sale of UK-based Danforth Care Homes. The divestment comes less than 18 months after Warwick acquired […]
Warwick Capital Partners, the UK-based global private equity and credit firm, has announced the sale of UK-based Danforth Care Homes. The divestment comes less than 18 months after Warwick acquired […]
UK: Warwick Capital Partners announces sale of Danforth Care Homes
November 11, 2025
Care Homes
M&A
M&A Deals
News
Real Assets
Ireland: Lanas Healthcare Technology launches with US$115m M&A funding to drive global healthtech growth
Lanas Healthcare Technology, a new global healthcare technology platform, has officially launched following its acquisition of Clanwilliam Group, a leading provider of electronic health record (EHR) solutions across the UK, […]
Lanas Healthcare Technology, a new global healthcare technology platform, has officially launched following its acquisition of Clanwilliam Group, a leading provider of electronic health record (EHR) solutions across the UK, […]
Ireland: Lanas Healthcare Technology launches with US$115m M&A funding to drive global healthtech growth
November 11, 2025
Buy Out
Life Sciences
M&A
Medtech – Healthcare IT
News
Sweden: EQT sets hard cap for EQT XI at €24bn
Swedish global investment firm, EQT, has set the hard cap for investor commitments of €24bn (US$27.74bn) for the EQT XI fund. The actual fund size is dependent on the outcome […]
Swedish global investment firm, EQT, has set the hard cap for investor commitments of €24bn (US$27.74bn) for the EQT XI fund. The actual fund size is dependent on the outcome […]
Sweden: EQT sets hard cap for EQT XI at €24bn
November 10, 2025
Buy Out
Healthcare
Life Sciences
News
EQT
US: Pfizer to acquire Metsera for US$10bn as Novo Nordisk withdraws
Nasdaq-listed Metsera, a clinical stage biotech aiming to reduce the burdens of obesity, has agreed to an amended merger agreement with Pfizer whereby Pfizer will acquire Metsera for up to US$86.25 per […]
Nasdaq-listed Metsera, a clinical stage biotech aiming to reduce the burdens of obesity, has agreed to an amended merger agreement with Pfizer whereby Pfizer will acquire Metsera for up to US$86.25 per […]
US: Pfizer to acquire Metsera for US$10bn as Novo Nordisk withdraws
November 10, 2025
M&A
News
Pharma
Metsera
Novo Nordisk
The Netherlands: Amber Implants appoints Vincent Gardès as CEO in advance of US market entry
Amber Implants, a medical technology company developing next-generation implants for spinal injuries, has appointed Vincent Gardès as CEO following his four-year tenure as chairman. The leadership transition marks a significant […]
Amber Implants, a medical technology company developing next-generation implants for spinal injuries, has appointed Vincent Gardès as CEO following his four-year tenure as chairman. The leadership transition marks a significant […]
The Netherlands: Amber Implants appoints Vincent Gardès as CEO in advance of US market entry
November 7, 2025
Life Sciences
Medtech – Medical Devices and Implants
News
People
Amber Implants
Denmark: Impilo embarks on Oticon Medical carve out from Demant
Impilo, a Nordic investment company focused lower-mid-market Nordic healthcare companies, has agreed to acquire Oticon Medical, a Denmark-based global provider of bone-anchored hearing solutions (BAHS), from Demant, a listed hearing […]
Impilo, a Nordic investment company focused lower-mid-market Nordic healthcare companies, has agreed to acquire Oticon Medical, a Denmark-based global provider of bone-anchored hearing solutions (BAHS), from Demant, a listed hearing […]
Denmark: Impilo embarks on Oticon Medical carve out from Demant
November 7, 2025
Buy Out
Life Sciences
M&A
Medtech – Medical Devices and Implants
News
France: Sandoz to boost in-house biosimilars capabilities with proposed acquisition of Just-Evotec Biologics EU SAS in Toulouse
Frankfurt-listed life science company Evotec has agreed to sell Just – Evotec Biologics Toulouse site to SIX-listed global generic and biosimilars company, Sandoz. The proposed acquisition aligns with the Sandoz […]
Frankfurt-listed life science company Evotec has agreed to sell Just – Evotec Biologics Toulouse site to SIX-listed global generic and biosimilars company, Sandoz. The proposed acquisition aligns with the Sandoz […]
France: Sandoz to boost in-house biosimilars capabilities with proposed acquisition of Just-Evotec Biologics EU SAS in Toulouse
November 6, 2025
M&A
Manufacturing – Generics
News
Pharma
Christian Wojczewski
UK: Octopus Capital funds two new care homes with Synergy Care
Octopus Capital, a UK specialist real estate lender and investor, has completed a £30m (US$39.22m) forward funding deal with Synergy Care Developments for the delivery of two new, purpose-built care […]
Octopus Capital, a UK specialist real estate lender and investor, has completed a £30m (US$39.22m) forward funding deal with Synergy Care Developments for the delivery of two new, purpose-built care […]
UK: Octopus Capital funds two new care homes with Synergy Care
November 6, 2025
Care Homes
News
Real Assets
Social Care
Acacia Care
Switzerland: MoonLake Immunotherapeutics prices US$75m underwritten offer
Nasdaq-listed MoonLake Immunotherapeutics, a Switzerland-based clinical-stage biotechnology company focused on advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, has priced an underwritten offering of 7,142,857 […]
Nasdaq-listed MoonLake Immunotherapeutics, a Switzerland-based clinical-stage biotechnology company focused on advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, has priced an underwritten offering of 7,142,857 […]
Switzerland: MoonLake Immunotherapeutics prices US$75m underwritten offer
November 5, 2025
Life Sciences
News
Public Equity
Leerink Partners
MoonLake Immunotherapeutics
Germany: NORD Holding invests in Material Analytischer Service
NORD Holding has acquired a majority stake in Germany-based Material Analytischer Service (MAS) as part of a succession solution. With NORD Holding’s involvement, MAS, a provider of reference standards/test kits […]
NORD Holding has acquired a majority stake in Germany-based Material Analytischer Service (MAS) as part of a succession solution. With NORD Holding’s involvement, MAS, a provider of reference standards/test kits […]
Germany: NORD Holding invests in Material Analytischer Service
November 5, 2025
Articles
Buy Out
M&A
News
Pharma
UK: Kester expands investment team with new hires
UK-based technology and life science investor, Kester Capital, Kester has expanded its investment team with the appointments of Ewan Rowlands and Heather Ellington as associates. Rowlands joins from PwC Strategy&, […]
UK-based technology and life science investor, Kester Capital, Kester has expanded its investment team with the appointments of Ewan Rowlands and Heather Ellington as associates. Rowlands joins from PwC Strategy&, […]
UK: Kester expands investment team with new hires
November 5, 2025
Life Sciences
News
People
Pharma
Ewan Rowlands
France: Lauxera targets final close of €500m for second fund
Healthcare focused asset manager, Lauxera Capital Partners, has closed its Growth Fund II at €400m, and is eyeing a final close of €500m by the end of the year, according […]
Healthcare focused asset manager, Lauxera Capital Partners, has closed its Growth Fund II at €400m, and is eyeing a final close of €500m by the end of the year, according […]
France: Lauxera targets final close of €500m for second fund
November 4, 2025
Healthcare
News
Venture
France
Lauxera Capital Partners
Switzerland: Healthcare Holding Schweiz acquires stake in Qunique
Healthcare Holding Schweiz, a provider of medical technology services and distribution solutions in Switzerland, has expanded its portfolio and strengthened its expertise in regulatory affairs and quality management through the […]
Healthcare Holding Schweiz, a provider of medical technology services and distribution solutions in Switzerland, has expanded its portfolio and strengthened its expertise in regulatory affairs and quality management through the […]
Switzerland: Healthcare Holding Schweiz acquires stake in Qunique
November 4, 2025
Life Sciences
M&A
Medtech – Hospital Equipment
News
Alex Enzler
Switzerland: Fremman Capital acquires Stingray Healthcare to create Europe’s largest cancer care platform
Fremman Capital has acquired Stingray Healthcare, a Switzerland headquartered European cancer care platform, from Jacobs Capital. Following the transaction, Fremman will merge Stingray with Amethyst Healthcare, acquired in August 2025, […]
Fremman Capital has acquired Stingray Healthcare, a Switzerland headquartered European cancer care platform, from Jacobs Capital. Following the transaction, Fremman will merge Stingray with Amethyst Healthcare, acquired in August 2025, […]
Switzerland: Fremman Capital acquires Stingray Healthcare to create Europe’s largest cancer care platform
November 3, 2025
Buy Out
Healthcare
Hospitals and Clinics
M&A
News
HPE Europe 2025: Navigating Healthcare investing and M&A in a competitive market
On 25 September, hundreds of healthcare professionals, investors, and industry leaders gathered in London for McDermott Will & Schulte’s Healthcare Private Equity (HPE) Europe 2025 conference. From keynote sessions with […]
On 25 September, hundreds of healthcare professionals, investors, and industry leaders gathered in London for McDermott Will & Schulte’s Healthcare Private Equity (HPE) Europe 2025 conference. From keynote sessions with […]
HPE Europe 2025: Navigating Healthcare investing and M&A in a competitive market
November 3, 2025
Analysis
Healthcare
Life Sciences
News
Pharma
Italy: AAVantgarde Bio closes US$141m Series B to accelerate gene therapies for Stargardt disease and Usher 1B syndrome
AAVantgarde Bio (AAVantgarde), a clinical-stage, biotechnology company pioneering therapies for inherited retinal diseases (IRDs), has closed a US$141m Series B financing round. The round was co-led by a new lead, Schroders […]
AAVantgarde Bio (AAVantgarde), a clinical-stage, biotechnology company pioneering therapies for inherited retinal diseases (IRDs), has closed a US$141m Series B financing round. The round was co-led by a new lead, Schroders […]
Italy: AAVantgarde Bio closes US$141m Series B to accelerate gene therapies for Stargardt disease and Usher 1B syndrome
November 3, 2025
Healthcare
Life Sciences
News
Ophthalmology
Venture
UK: Narayana Health expands global footprint with UK-based Practice Plus Group Hospitals
Narayana Health, an India-headquartered global healthcare provider, has moved into the UK healthcare market with the acquisition of Practice Plus Group Hospitals for a reported £188.78m (US$248m). The acquisition extends […]
Narayana Health, an India-headquartered global healthcare provider, has moved into the UK healthcare market with the acquisition of Practice Plus Group Hospitals for a reported £188.78m (US$248m). The acquisition extends […]
UK: Narayana Health expands global footprint with UK-based Practice Plus Group Hospitals
October 31, 2025
Healthcare
Hospitals and Clinics
M&A
News
Baird
Germany: Tubulis announces second closing of Series C
Tubulis has held the final close of its recently announced first close of its massive Series C at €344m (US$397m). The round welcomed additional new investors Fidelity Management and Research […]
Tubulis has held the final close of its recently announced first close of its massive Series C at €344m (US$397m). The round welcomed additional new investors Fidelity Management and Research […]
Germany: Tubulis announces second closing of Series C
October 31, 2025
Life Sciences
News
Pharma
Venture
Blackstone
Switzerland: Oculis prices US$110m financing to accelerate development of Privosegtor
Oculis Holding, a listed global biopharmaceutical company focused on innovations to address unmet medical needs in ophthalmology and neuro-ophthalmology, has priced an oversubscribed US$110m financing to accelerate Privosegtor development. The […]
Oculis Holding, a listed global biopharmaceutical company focused on innovations to address unmet medical needs in ophthalmology and neuro-ophthalmology, has priced an oversubscribed US$110m financing to accelerate Privosegtor development. The […]
Switzerland: Oculis prices US$110m financing to accelerate development of Privosegtor
October 30, 2025
News
Pharma
Public Equity
Arctica Finance
JP Morgan
Investing in women’s health: growth, innovation and the next wave of FemTech opportunities
Long overlooked by mainstream investors, women’s health is finally attracting serious attention. With sustained growth, rising consumer demand, and a shift toward preventive and personalised care, women’s health and FemTech […]
Long overlooked by mainstream investors, women’s health is finally attracting serious attention. With sustained growth, rising consumer demand, and a shift toward preventive and personalised care, women’s health and FemTech […]
Investing in women’s health: growth, innovation and the next wave of FemTech opportunities
October 30, 2025
Analysis
Articles
Healthcare
Life Sciences
Pharma
US: Thermo Fisher Scientific to acquire Clario from Astorg, Nordic Capital, Novo Holdings and Cinven for up to US$9.4bn
New York-listed Thermo Fisher Scientific, a world leader in life science and clinical research, is to acquire US-based Clario Holdings, a provider of endpoint data solutions to the clinical trial […]
New York-listed Thermo Fisher Scientific, a world leader in life science and clinical research, is to acquire US-based Clario Holdings, a provider of endpoint data solutions to the clinical trial […]
US: Thermo Fisher Scientific to acquire Clario from Astorg, Nordic Capital, Novo Holdings and Cinven for up to US$9.4bn
October 30, 2025
M&A
News
Pharma
Services – CRO/CMO/CDMO
Astorg
Netherlands: Ottobock strengthens role as largest shareholder in Onward Medical following private placement
Euronext-listed Onward Medical, a medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injuries, last week raised €50.85m (US$59.2m) through a private […]
Euronext-listed Onward Medical, a medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injuries, last week raised €50.85m (US$59.2m) through a private […]
Netherlands: Ottobock strengthens role as largest shareholder in Onward Medical following private placement
October 29, 2025
Life Sciences
Medtech – Medical Devices and Implants
News
Public Equity
a.s.r. Asset Management
France: Archimed Diagnostics closes acquisition of ARK Diagnostics
Archimed Diagnostics has closed its carve-out of US-based ARK Diagnostics from listed South Korean specialty chemical company, Soulbrain Holdings. ARK is a global developer and manufacturer of specialty immunoassay In […]
Archimed Diagnostics has closed its carve-out of US-based ARK Diagnostics from listed South Korean specialty chemical company, Soulbrain Holdings. ARK is a global developer and manufacturer of specialty immunoassay In […]
France: Archimed Diagnostics closes acquisition of ARK Diagnostics
October 29, 2025
Buy Out
IVD – Tools
Life Sciences
M&A
Medtech – Diagnostics
Switzerland: EQT, ADIA and Auba sell another 8.4% of Galderma
EQT, ADIA and Auba have sold another 8.4% of their holding in Switzerland-based skincare specialist in an overnight share sale, say reports. Bloomberg reports that the trio sold 20 million […]
EQT, ADIA and Auba have sold another 8.4% of their holding in Switzerland-based skincare specialist in an overnight share sale, say reports. Bloomberg reports that the trio sold 20 million […]
Switzerland: EQT, ADIA and Auba sell another 8.4% of Galderma
October 28, 2025
Cosmetic & Aesthetics
Healthcare
News
Public Equity
BoA Securities
The latest insights from
Compass Carter Osborne
Culture in flux: rebuilding trust in a multi-generational workforce
Culture in flux: rebuilding trust in a multi-generational workforce
October 24, 2025
Healthcare
Insight
